IL6 and lung carcinoma: In lung cancer mouse models, blocking or deleting IL-6 reveals a delay in tumor progression and metastasis through deactivation of the IL-6/STAT3 pathway and cell proliferation regulator cyclin D1, as well as through enhancement of tumor cell apoptosis (70).